SEC Comment Letter for ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895) (RCKT) — Dec 1, 2017

ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)
Date: Dec. 1, 2017 · CIK: 0001281895 · Accession: 0000000000-17-042191

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

December 1, 2017

Author

David P. Southwell

Form

UPLOAD

Company

ROCKET PHARMACEUTICALS, INC. (RCKT, RCKTW) (CIK 0001281895)

Letter

December 1, 2017 David P. Southwell President and Chief Executive Officer Inotek Pharmaceuticals Corporation 91 Hartwell Avenue Lexington, Massachusetts 02421 Inotek Pharmaceuticals Corporation Preliminary Proxy Statement on Schedule 14A Filed October 12, 2017 File No. 001-36829Re: Dear Mr. Southwell: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Andrew H. Goodman, Esq.

Show Raw Text

December 1, 2017
David P. Southwell
President and Chief Executive Officer
Inotek Pharmaceuticals Corporation
91 Hartwell Avenue
Lexington, Massachusetts 02421
Inotek Pharmaceuticals Corporation
Preliminary Proxy Statement on Schedule 14A
Filed October 12, 2017
File No. 001-36829Re:
Dear Mr. Southwell:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence by the staff.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Andrew H. Goodman, Esq.

SecProbe.io